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PLINICAL RESEARCH Clinical Trials
ombined Angioplasty and Pharmacological
ntervention Versus Thrombolysis Alone in
cute Myocardial Infarction (CAPITAL AMI Study)
ichel R. Le May, MD, FACC, George A. Wells, PHD, Marino Labinaz, MD, FACC,
ichard F. Davies, MD, FACC, Michele Turek, MD, Danielle Leddy, MD, Justin Maloney, MD,
im McKibbin, MD, Brendan Quinn, MD, Rob S. Beanlands, MD, Chris Glover, MD,
ean-François Marquis, MD, Edward R. O’Brien, MD, FACC, William L. Williams, MD, FACC,
yall A. Higginson, MD, FACC
ttawa, Ontario, Canada
OBJECTIVES We compared a strategy of tenecteplase (TNK)-facilitated angioplasty with one of TNK
alone in patients presenting with high-risk ST-segment elevation myocardial infarction
(STEMI).
BACKGROUND Previous trials show that thrombolysis followed by immediate angioplasty for the treatment
of STEMI does not improve ischemic outcomes compared with thrombolysis alone and is
associated with excessive bleeding complications. Since the publication of these trials,
however, significant pharmacological and technological advances have occurred.
METHODS We randomized 170 patients with high-risk STEMI to treatment with TNK alone (84
patients) or TNK-facilitated angioplasty (86 patients). The primary end point was a
composite of death, reinfarction, recurrent unstable ischemia, or stroke at six months.
RESULTS At six months, the incidence of the primary end point was 24.4% in the TNK-alone group
versus 11.6% in the TNK-facilitated angioplasty group (p 0.04). This difference was driven
by a reduction in the rate of recurrent unstable ischemia (20.7% vs. 8.1%, p  0.03). There
was a trend toward a lower reinfarction rate with TNK-facilitated angioplasty (14.6% vs.
5.8%, p  0.07). No significant differences were observed in the rates of death or stroke.
Major bleeding was observed in 7.1% of the TNK-alone group and in 8.1% of the
TNK-facilitated angioplasty group (p  1.00).
CONCLUSIONS In patients presenting with high-risk STEMI, TNK plus immediate angioplasty reduced the
risk of recurrent ischemic events compared with TNK alone and was not associated with an
increase in major bleeding complications. (J Am Coll Cardiol 2005;46:417–24) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.042the American College of Cardiology Foundation
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carly, complete, and sustained reperfusion of the infarct-
elated artery (IRA) improves survival in patients presenting
ith ST-segment elevation myocardial infarction (STEMI)
1–3). Reperfusion with thrombolysis or percutaneous cor-
nary intervention (PCI) is the current standard of care for
TEMI (4). The advantages of the former are ease of
dministration and widespread availability. Although fibrin-
pecific thrombolytic agents can achieve early patency of the
RA, complete flow is restored in only 60% of patients (5).
ngioplasty accomplishes this in up to 95% of patients and
s associated with a lower rate of re-occlusion (5); however,
elays associated with patient transfer and catheterization
eam mobilization, plus the limited accessibility to cathe-
erization facilities, might significantly prolong the time to
echanical reperfusion.
From the Division of Cardiology, University of Ottawa, Ottawa, Ontario, Canada.
his study was supported by a peer-reviewed grant from the Canadian Institutes of
ealth Research (CIHR) and a CIHR Industry-Partnered Program with Hoffmann
a-Roche Limited, Canada, and Guidant Corporation Canada.e
Manuscript received December 8, 2004; revised manuscript received April 3, 2005,
ccepted April 13, 2005.Combining these strategies has the potential to provide
he speed of pharmacological reperfusion with the more
omplete and sustained reperfusion provided by PCI. Al-
hough previous trials found this approach was complicated
y increased bleeding, with no apparent clinical benefit
ompared with thrombolysis alone (6–8), these were per-
ormed without weight-adjusted bolus thrombolytic agents
r coronary stents. These pharmacological and technologi-
al advances could alter the clinical outcomes. Therefore, we
onducted a randomized multi-center trial, comparing
hrombolysis alone to thrombolysis with immediate transfer
or PCI.
ETHODS
atient selection. The study was conducted in four Ot-
awa hospitals, with the interventional facility located at the
niversity of Ottawa Heart Institute. Patients presenting
6 h of the onset of chest discomfort of 30 min duration
nd having 1 mm ST-segment elevation in two or more
ontiguous leads or left bundle branch block on a 12-lead
lectrocardiogram were eligible if they had one of the
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Thrombolytic-Facilitated Angioplasty August 2, 2005:417–24ollowing high-risk criteria: 1) anterior infarction with
T-segment elevation 2 mm in each of two contiguous
recordial leads; 2) extensive non-anterior infarction: eight
r more leads with 1 mm ST-segment elevation or
epression or both, or the sum of ST-segment elevation
20 mm; 3) Killip class 3; or 4) systolic blood pressure
100 mm Hg. The criteria for exclusion were active
leeding, history of stroke, or central nervous system dam-
ge, major surgery or trauma within three months, uncon-
rolled hypertension (systolic blood pressure 200 mm Hg
nd/or diastolic blood pressure 120 mm Hg), prolonged
10 min) cardiopulmonary resuscitation, a blood coagula-
ion disorder, current warfarin treatment, previous coronary
rtery bypass graft surgery (CABG), PCI within six months,
lycoprotein IIb/IIIa inhibitors within seven days, 5,000
U of unfractionated heparin within 6 h, a therapeutic dose
f any low molecular weight heparin within six h, intoler-
nce to aspirin, other illness likely to result in death within
2 months, pregnancy, a creatinine 300 mol/l (3.40
g/dl), cardiogenic shock, and severe contrast allergy. The
rotocol was approved by the institutional review board at
ach hospital; all patients provided informed consent.
tudy design. All patients received 160 mg of chewable
spirin immediately, and aspirin 325 mg daily thereafter.
ligible patients were randomized to tenecteplase (TNK)
lone or TNK followed by immediate transfer for PCI. All
atients received weight-adjusted TNK and weight-
djusted unfractionated heparin as reported in the Assess-
ent of the Safety and Efficacy of a New Thrombolytic
gent (ASSENT)-3 trial (9).
In patients assigned to TNK-facilitated PCI, heparin was
topped upon arrival at the catheterization laboratory, and
oronary angiography was performed as soon as possible.
ngioplasty was performed unless angiography identified
iffuse disease not amenable to revascularization or the IRA
ad Thrombolysis In Myocardial Infarction (TIMI) (10)
ow grade 3 and70% stenosis at the culprit site. Coronary
tenting was performed using ACS Multilink Penta or Zeta
tents (Guidant, Advanced Cardiovascular Systems Inc.,
emecula, California). Angioplasty with balloon alone was
erformed if the IRA was small or if technical difficulties
revented delivery of a stent. Glycoprotein IIb/IIIa inhibi-
ors were not routinely used. Bolus doses of heparin were
Abbreviations and Acronyms
ACT  activated clotting time
ASSENT  Assessment of the Safety and Efficacy of a
New Thrombolytic Agent
CABG  coronary artery bypass graft surgery
IRA  infarct-related artery
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
TNK  tenecteplasesed, targeting an activated clotting time (ACT) of 250 s. peparin was not routinely reinitiated after the procedure.
atients received clopidogrel 300 mg as a single dose and 75
g daily for at least one month. The femoral arterial
pproach without any closure device was used for cardiac
atheterization and femoral sheaths were removed 8 to 12 h
fter the TNK bolus.
In patients assigned to TNK alone, indications for acute
ngiography were persistent chest pain and ST-segment
levation 90 min after initiation of thrombolysis or dete-
iorating hemodynamic status.
All patients had radionuclide ventriculography scheduled
t one week and at 30 days, and exercise testing (Bruce
rotocol) at 30 days after randomization.
nd points and definitions. The primary end point was a
omposite of death, recurrent myocardial infarction, recur-
ent unstable ischemia, or stroke at six months after ran-
omization. Reinfarction was defined as recurrent ischemic
ymptoms at rest lasting 30 min and accompanied by: 1)
ew or recurrent ST-segment elevation of 1 mm in any
ontiguous leads; 2) new left bundle branch block; or 3)
e-elevation in serum creatine kinase level to greater than
wice the upper limit of normal and 50% above the lowest
evel measured after infarction. If reinfarction occurred
ithin 18 h, enzyme criteria were not used. Recurrent
nstable ischemia was defined as recurrent symptoms of
schemia at rest associated with new ST-segment or T-wave
hanges, hypotension, or pulmonary edema. Stroke was
efined as a focal neurological deficit, compatible with
amage in the territory of a major cerebral artery with signs
r symptoms persisting for 24 h and was classified as
emorrhagic or non-hemorrhagic according to computer-
zed tomography. Congestive heart failure was documented
hen any two of the following were present: 1) dyspnea; 2)
ulmonary venous congestion with interstitial or alveolar
dema on chest radiograph; 3) crackles greater than or equal
o one-third of the way up the lung fields; and 4) third heart
ound associated with tachycardia. Cardiogenic shock was
efined as systolic blood pressure80 mm Hg not respond-
ng to fluid expansion and requiring intravenous inotropic
upport or intra-aortic balloon counterpulsation. Episodes
f bleeding were classified as minor or major according to
he TIMI criteria (10). An independent monitor verified all
ata entry into the case-report forms against the patient’s
edical records. A blinded, independent clinical event
ommittee adjudicated all possible events related to primary
utcome, congestive heart failure, and shock. The Data
afety Monitoring Committee reviewed the data at regular
ntervals.
tatistical analysis. On the basis of previous reports (11–
5), we anticipated that the occurrence of the primary end
oint would be 40% in the TNK alone group and 20% in the
NK-facilitated PCI group at six months (a 50% reduc-
ion). With a two-sided alpha of 5%, a power of 80%, and
non-adherence rate of 2% (14), a total of 170 patients (85
atients per group) were required. Statistical analysis was
erformed according to the intention-to-treat principle.
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Figure 1. Randomization and disposition of patients.
Values are given as percentages or medians (25th, 75th percentiles
TNK  tenecteplase.
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August 2, 2005:417–24 Thrombolytic-Facilitated Angioplastyalues for binary outcomes are reported as frequencies and
ercents with group comparisons using the Fisher exact test;
alues for continuous outcomes are reported as medians and
nterquartile ranges with group comparisons using the
ann-Whitney rank sum test; and time-to-event outcomes
re reported using Kaplan-Meier curves with groups com-
arisons using the log-rank test. Two-sided tests and 95%
onfidence intervals were used. Analyses were performed
ith SAS statistical software (version 8.02, SAS Institute,
ary, North Carolina).
ESULTS
aseline characteristics of the patients. Between August
001 and January 2004, 170 patients were enrolled: 84 were
andomly assigned to TNK alone, and 86 to TNK-
acilitated PCI. The details of randomization and disposi-
ion of the patients are outlined in Figure 1. The two
reatment groups were well matched as to baseline charac-
eristics (Table 1). The infarction location was anterior in
7.6% of patients assigned to TNK alone and anterior in
2.3% of the patients assigned to TNK-facilitated PCI.
Alone Group
n  84)
TNK-Facilitated
Angioplasty Group
(n  86) p Value
(51, 66) 57 (50, 67) 0.82
10.7 18.6 0.19
76.1 75.6 1.00
44.0 44.2 1.00
11.9 20.9 0.15
63.1 54.7 0.28
16.7 23.2 0.34
10.7 16.3 0.37
3.6 5.8 0.72
(60, 84) 73 (61, 85) 0.51
(119, 149) 128 (115, 148) 0.61
(70, 91) 79 (65, 89) 0.16
47.6 52.3 0.65
79.8 79.1 1.00
(167, 178) 173 (165, 178) 0.25
(67, 95) 80 (68, 91) 0.72
(48, 141) 68 (45, 115) 0.68
(25, 54) 34 (22, 50) 0.48
(5, 6) 5 (5, 10) 0.12
(34, 61) 43 (32, 55) 0.40
(90, 208) 120 (90, 153) 0.61
95 (73, 106)
104 (95, 111)
88 (63, 102)
132 (113, 150)
204 (172, 250)
52.3
11.6
36.0Table 1. Baseline Characteristics of the Patients
TNK-
(
Age, yrs 58
Age 75 yrs
Male gender
Hypertension
Diabetes
Current smoking
Previous angina
Previous myocardial infarction
Previous angioplasty
Heart rate, beats/min 71
Systolic blood pressure, mm Hg 130
Diastolic blood pressure, mm Hg 80
Anterior index myocardial infarction
Killip class 1
Height, cm 173
Weight, kg 79
Critical time intervals, min
Onset of symptoms to hospital arrival 64
Hospital arrival to randomization 37
Randomization to TNK bolus 5
Hospital arrival to TNK bolus 45
Onset of symptoms to TNK 120
Randomization to first balloon inflation
Randomization to first balloon inflation in
transferred patients, n  39
Randomization to first balloon inflation in
non-transferred patients, n  46
Hospital arrival to first balloon inflation
Onset of symptoms to first balloon inflation
Infarct-related artery
Left anterior descending
Left circumflex
Right coronary).
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Thrombolytic-Facilitated Angioplasty August 2, 2005:417–24reatment received. All randomized patients were treated
ccording to protocol except for one patient assigned to the
acilitated PCI group who was treated with activase instead
f TNK and transferred for angiography outside the pre-
pecified 3-h window.
The median time from symptom onset to TNK admin-
stration was 120 min in both groups. Among the 86
atients assigned to TNK-facilitated PCI, 40 required
mbulance transfer, and 85 (99%) had coronary angiography
ithin 3 h from the time of randomization. Of the latter, 79
atients (91%) underwent PCI, with a median time from
andomization to first balloon inflation of 95 min. Stents
ere implanted in 77 patients (89%), and PCI with balloon
lone was performed in 2 patients (2.3%). Platelet glyco-
rotein IIb/IIIa inhibitors were prescribed in 12 patients
14%) and used only when the angiographic result was
uboptimal. On the initial angiogram, a patent IRA (TIMI
ow grade 2 or 3) was present in 84% of patients assigned
o TNK-facilitated PCI, and TIMI flow grade 3 in 52%.
fter PCI, patency increased to 97%, with 89% having
IMI flow grade 3. Angiographic success (stenosis of
50% and TIMI flow grade 3) was observed in 92% of the
9 patients who underwent facilitated PCI. The median
eak ACT during the procedure was 207 s (interquartile
ange, 180 to 228). No patient required emergency CABG.
The types of cardiac medication prescribed did not differ
etween the two groups except for clopidogrel, which was
rescribed to 91% of patients assigned to TNK-facilitated
CI and to 57% of patients assigned to TNK alone (p
0.001). At discharge, 96% of patients were prescribed
spirin, 93% beta-blockers, 90% angiotensin-converting
able 2. Occurrence of the Primary End Point*
TNK-Alone Group
(n  84)
n-hospital
Death 3 (3.6)
Reinfarction 11 (13.1)
Recurrent unstable ischemia† 15 (17.9)
Stroke 1 (1.2)
Death, reinfarction, or stroke 14 (16.7)
Primary end point 18 (21.4)
t 30 days
Death 3 (3.6)
Reinfarction 11 (13.3)
Recurrent unstable ischemia† 15 (18.1)
Stroke 1 (1.2)
Death, reinfarction, or stroke 14 (16.9)
Primary end point 18 (21.7)
t 6 months
Death 3 (3.7)
Reinfarction 12 (14.6)
Recurrent unstable ischemia† 17 (20.7)
Stroke 1 (1.2)
Death, reinfarction, or stroke 15 (18.3)
Primary end point 20 (24.4)alues are given as number (percentages). *Death, reinfarction, recurrent unstable ischemia
TNK  tenecteplase.nzyme inhibitors, and 92% lipid-lowering drugs. At six
onths, 96% of patients were taking aspirin, 84% beta-
lockers, 84% angiotensin-converting enzyme inhibitors,
nd 91% lipid-lowering drugs.
rimary end point events. Complete data were available in
ll but one patient (99.4%) at 30 days and all but two
atients (98.8%) at six months. Patients assigned to TNK-
acilitated PCI experienced fewer primary end point events
t 30 days (21.7% vs. 9.3%, p  0.03) and at 6 months
24.4% vs. 11.6%, p  0.04) (Table 2). A reduction in
einfarction and recurrent unstable ischemia accounted for
he superiority of TNK-facilitated PCI over TNK alone,
ecause there was no difference in either death or stroke
etween groups. The Kaplan-Meier curves for the cumula-
ive rate of the primary end point indicate that the relative
enefit of TNK-facilitated PCI occurred mostly within the
rst week after randomization (Fig. 2).
leeding. Major bleeding during hospitalization occurred in
ix patients (7.1%) in the TNK-alone group and in seven
atients (8.1%) in the TNK-facilitated PCI group (relative
isk, 1.14; 95% confidence interval, 0.40 to 3.25; p  1.0)
Table 3). Blood transfusion was required in two patients
2.4%) assigned to TNK alone and in five patients (6.0%)
ssigned to TNK-facilitated PCI (relative risk, 2.44; 95%
onfidence interval, 0.49 to 12.25; p  0.44). One patient in
ach group experienced a stroke due to intracranial
emorrhage.
eft ventricular function. There was no difference between
atients assigned to TNK alone or to TNK-facilitated PCI
n the occurrence of congestive heart failure or cardiogenic
hock (Table 3). There was no difference between groups in
K-Facilitated
oplasty Group
(n  86)
Relative Risk
(95% Confidence Interval) p Value
2 (2.3) 0.65 (0.11–3.80) 0.68
3 (3.5) 0.27 (0.08–0.92) 0.03
5 (5.8) 0.33 (0.12–0.86) 0.02
1 (1.2) 0.98 (0.06–15.36) 1.00
5 (5.8) 0.35 (0.13–0.93) 0.03
7 (8.1) 0.38 (0.17–0.86) 0.02
2 (2.3) 0.64 (0.11–3.75) 0.68
4 (4.7) 0.35 (0.12–1.06) 0.06
6 (7.0) 0.39 (0.16–0.95) 0.04
1 (1.2) 0.97 (0.61–15.18) 1.00
6 (7.0) 0.41 (0.17–1.03) 0.06
8 (9.3) 0.43 (0.20–0.93) 0.03
3 (3.5) 0.95 (0.20–4.59) 1.00
5 (5.8) 0.40 (0.15–1.08) 0.07
7 (8.1) 0.39 (0.17–0.90) 0.03
1 (1.2) 0.95 (0.60–14.99) 1.00
8 (9.3) 0.51 (0.23–1.14) 0.12
10 (11.6) 0.48 (0.24–0.96) 0.04TN
Angi, or stroke. †Includes patients with reinfarction.
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August 2, 2005:417–24 Thrombolytic-Facilitated Angioplastyhe left ventricular ejection fraction measured at one week
nd 30 days, and in treadmill exercise duration measured at
0 days.
nscheduled cardiac procedures. During the index hos-
italization, non-protocol catheterization was performed in
6 patients assigned to TNK alone (66.7%) versus 12
atients assigned to TNK-facilitated PCI (14.0%; p 
.001) (Table 4). Among patients assigned to TNK-alone,
he indication for catheterization was recurrent ischemia in
9.3% and failure of thrombolysis (rescue) in 9.5%. Non-
rotocol PCI was performed in 42 patients in the TNK-
lone group (50.0%), compared with 12 patients in the
igure 2. Kaplan-Meier curves showing the cumulative incidence of the
rimary end point at 30 days and at six months. The primary end point was
composite of death, reinfarction, recurrent unstable ischemia, or stroke
fter random assignment to treatment with tenecteplase (TNK) alone or
NK-facilitated angioplasty. In the TNK-facilitated angioplasty group,
here was a 58% relative reduction in the risk of the primary end point at
0 days (log-rank p  0.03) (top). At six months, there was a 53%
eduction in the risk of the primary end point in the TNK-facilitated
ngioplasty group (log-rank p  0.03) (bottom).NK-facilitated PCI group (14.0%; p  0.001). In 7 of ihese 12 patients, the reason for unscheduled catheterization
as PCI involving a coronary artery other than the IRA
erformed.
At six months, 53.7% of patients assigned to TNK alone
equired unscheduled revascularization versus 16.3% of
atients assigned to TNK-facilitated PCI (p 0.001). Only
wo patients required CABG, both in the TNK-alone
roup.
ISCUSSION
his trial assessed the effectiveness and safety of full-dose
eight-adjusted TNK followed by immediate transfer for
acilitated PCI in patients presenting with high-risk
TEMI. Compared with TNK alone, this strategy was
ssociated with a significant reduction in the combined end
oint of death, reinfarction, recurrent unstable ischemia, or
troke, at 30 days and at 6 months, and was not associated
ith an increase in major bleeding. These results suggest
hat a strategy of full-dose thrombolysis followed by imme-
iate transfer for PCI might be safe and might be superior
o thrombolysis-alone.
Facilitated PCI combines the early reperfusion associated
ith immediate pharmacological therapy with the com-
leteness and sustainability of reperfusion provided by PCI.
n addition to limiting myocardial necrosis, successful reper-
usion before PCI simplifies the technical performance of
he procedure by allowing better visualization of the IRA
nd its branches. Previous trials failed to show any clinical
enefit of immediate PCI after full-dose thrombolysis, and
leeding complications increased (6–8); however, since the
ublication of these trials, significant advances have oc-
urred in pharmacological therapy and PCI technology. The
ecent introduction of the highly fibrin-specific, weight-
djusted, single-bolus tissue plasminogen activator TNK
implifies the administration of thrombolysis and is associ-
ted with fewer major bleeding complications when coupled
ith a reduced dose of heparin (11). Aspirin is now given
mmediately to all patients to prevent re-occlusion, whereas
n the TIMI IIa study, aspirin was given to only one-third
f the patients on the first day of hospitalization (6). The
urrent widespread use of stents with primary PCI yields
uperior clinical outcomes over those previously obtained
ith balloon alone (16). During PCI, heparin dosing is now
uided by the ACT, and the addition of thienopyridines has
educed the incidence of abrupt vessel closure after PCI
17). Taken together, these advances provide a plausible
xplanation of why thrombolysis-facilitated PCI might now
e safe and effective.
Retrospective studies suggest that an open artery before
rimary PCI portends a better prognosis (18–20). In one
tudy, a patent IRA at initial angiography correlated with
ess cardiogenic shock, a higher left ventricular ejection
raction, and better survival (18–20). Two other studies
ound that pre-procedural TIMI flow grade 3 was an
ndependent predictor of late survival (19,20). The Primary
A
s
a
p
v
P
i
s
m
r
t
P
c
T
B
C
C
L
E
L
R
V des pa
422 Le May et al. JACC Vol. 46, No. 3, 2005
Thrombolytic-Facilitated Angioplasty August 2, 2005:417–24ngioplasty Combined with Thrombolysis (PACT) study
howed that pre-treatment with half-dose tissue-plasminogen
ctivator appears to be safe and achieves higher pre-
rocedural TIMI flow grade 3 compared with placebo, 33%
ersus 15% (21). In our study, full-dose TNK-facilitated
CI was associated with pre-procedural TIMI flow grade 3
n 52% of patients at a median of 95 min. These results are
able 3. Occurrence of Secondary End Points
TNK-
(
leeding with initial treatment
Baseline hemoglobin per patient, g/l 151
Nadir hemoglobin per patient, g/l 125
Average drop in hemoglobin per patient, g/l 22
Transfusion required 2
Major bleeding 6
Minor bleeding 11
ongestive heart failure*
At 30 days 10
At 6 months 12
ardiogenic shock
At 30 days 3
At 6 months 3
eft ventricular ejection fraction
At 1 week 53
At 30 days 55
Difference 3
xercise test at 30 days
Duration, min 6.8
ength of stay (index hospitalization) 6.0
e-hospitalization per patient 12
alues are given as number (percentages) or medians (25th, 75th percentiles). *Inclu
TNK  tenecteplase.
Table 4. Unscheduled Cardiac Procedures
Cardiac Procedure
TNK-Al
(n
During index hospitalization
Coronary angiogram 56
Time to angiography, days 2.5
Indication
Recurrent ischemia 33
Failed thrombolysis 8
Congestive heart failure/shock 2
Ventricular tachycardia 3
Physician preference 8
Other 2
PCI 42
Time to PCI, days 2.0
CABG 2
At 30 days
Coronary angiogram 56
PCI 42
CABG 2
At 6 months
Coronary angiogram 60
PCI 44
CABG 2Values are given as number (percentages) or medians (25th, 75th p
CABG  coronary artery bypass graft surgery; PCI  percutanimilar to those achieved in the TIMI 10b study (22) and in
arked contrast to the TIMI flow grade 3 of 20%
eported at the time of primary PCI (20,23).
Significant delays associated with transfer to the cathe-
erization facility remain an important drawback to primary
CI (24). Our results indicate that TNK-facilitated PCI
an bridge the time gap between diagnosis and balloon
Group
4)
TNK-Facilitated
Angioplasty Group
(n  86) p Value
157) 148 (141, 159) 0.73
136) 129 (111, 137) 0.94
29) 22 (15, 33) 0.53
5 (6.0) 0.44
7 (8.1) 1.00
) 20 (23.3) 0.11
) 11 (12.8) 1.00
) 12 (14.0) 1.00
4 (4.7) 1.00
4 (4.7) 1.00
0 n  75
58) 49 (41, 55) 0.09
61) 52 (45, 59) 0.08
7) 2 (2, 8) 0.74
3 n  59
9.0) 6.4 (4.6, 8.7) 0.33
8.0) 5.0 (4.0, 7.0) 0.02
) 15 (17.9) 0.83
tients with cardiogenic shock.
roup
)
TNK-Facilitated
Angioplasty Group
(n  86) p Value
12 (14.0) 0.001
) 3.5 (1.5, 6.0)
5 (5.8)
—
0 (0)
0 (0)
0 (0)
7 (8.1)*
12 (14.0) 0.001
) 3.5 (1.5, 6.0)
0 (0.0) 0.24
12 (13.9) 0.001
12 (13.9) 0.001
0 (0.0) 0.24
14 (16.3) 0.001
14 (16.3) 0.001
0 (0.0) 0.24Alone
n  8
(141,
(115,
(15,
(2.4)
(7.1)
(13.1
(12.1
(14.6
(3.6)
(3.7)
n  6
(46,
(50,
(1,
n  5
(6.0,
(5.5,
(14.5one G
 84
(66.6)
(0, 6.0
(39.3)
(9.5)
(2.4)
(3.6)
(9.5)
(2.4)
(50.0)
(0, 5.0
(2.4)
(67.5)
(50.6)
(2.4)
(73.2)
(53.7)
(2.4)ercentiles). *Staged angioplasty procedures.
eous coronary intervention; TNK  tenecteplase.
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August 2, 2005:417–24 Thrombolytic-Facilitated Angioplastynflation. Although the time window in which facilitated
CI confers benefit is unknown, we found that the Kaplan-
eier curves separate within the first 24 h, suggesting that
he observed benefits are attenuated by delaying coronary
ngiography. Conversely, in settings where door-to-balloon
ntervals are very short, the benefits of facilitated PCI might
e less because restoration of blood flow to the IRA before
CI will occur in fewer patients.
It is plausible that TNK-facilitated PCI will be superior
o primary PCI because of the benefits provided by earlier
eperfusion, particularly in settings where transportation
ime and logistics might delay PCI, although this has yet to
e proven. The ongoing ASSENT-4 trial is comparing
NK-facilitated PCI with primary PCI and will test this
ypothesis directly.
Glycoprotein IIb/IIIa inhibitors were used sparingly to
void bleeding complications that might otherwise have
risen by combining these drugs with full-dose thrombolytic
herapy. A systematic overview of abciximab in primary PCI
uggests that it might be an important adjunct (25), and one
andomized trial has reported superior clinical outcomes
ith abciximab-facilitated PCI compared with primary PCI
lone (26). Larger trials addressing the role of pharmaco-
ogic reperfusion therapy with abciximab alone or in com-
ination with reduced-dose reteplase, followed by PCI, are
urrently underway (27,28).
Our results complement two recently published studies
hat support early intervention after thrombolysis (29,30).
he Southwest German Interventional Study in Acute
yocardial Infarction (SIAM III) randomly assigned 163
atients initially treated with thrombolysis to immediate
tenting or to elective stenting after two weeks. Immediate
tenting performed 6 h after thrombolysis was associated
ith a significant reduction of the six-month composite of
eath, reinfarction, target lesion revascularization, and isch-
mic events (25.6% vs. 50.6%) (29). The Grupo de Análisis
e la Cardiopatía Isquémica Aguda-1 (GRACIA-1) ran-
omly assigned 500 patients after thrombolytic therapy to a
outine invasive strategy within 24 h of thrombolysis versus
n ischemia-guided approach (30). The composite of death,
einfarction, or revascularization at one year was lower in the
arly invasive group (9% vs. 21%).
The percent risk reduction achieved with TNK-
acilitated PCI compared with TNK alone was as predicted,
lthough primary end point events were fewer than ex-
ected. Several factors might have contributed to this,
ncluding relatively short symptom-onset to treatment times
1), aggressive revascularization during the index hospital-
zation (31), and rigorous application of practice guidelines
n prescribing beta-blockers, angiotensin-converting en-
yme inhibitors, and lipid-lowering drugs (32).
tudy limitations. Our study of a small, but well-defined
ohort is the first contemporary randomized control trial to
igorously assess the merits of TNK-facilitated PCI against
NK alone. Lower rates of recurrent unstable ischemia andeinfarction with TNK-facilitated PCI compared withNK alone accounted for lowering the rate of occurrence of
he primary end point. Although our study was not powered
o detect differences in mortality, larger studies indicate that
ecurrent ischemia or reinfarction occurring after thrombol-
sis are associated with increased morbidity, mortality, and
esource utilization (33–35). Regarding major bleeding, our
tudy is too small to provide reliable estimates of the relative
afety.
onclusions. This study shows that a strategy of TNK-
acilitated angioplasty for patients presenting with high-risk
TEMI appears to be safe and reduces the risk of recurrent
schemic events compared with TNK alone. Larger ran-
omized trials, including comparison with primary PCI
lone and studies evaluating the cost-effectiveness of TNK-
acilitated PCI, will further define its role.
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